Quark has a broad pipeline of siRNA drug candidates based on Quark’s proprietary RNAi technology that includes internally developed novel siRNA structures and chemistry which the Company believes provide it with freedom to operate in the siRNA intellectual property arena. Quark also has IP covering non-invasive delivery of siRNA to target tissues including the eye, inner ear, kidney, lung, spinal cord and brain. The programs aim to develop drugs to treat diseases that are unmet medical needs Among the pipeline programs:
Among the pipeline programs:

Neuroprotection and neural regeneration program.
Included in this category are programs in diseases of the central nervous system, and diseases of the eyes and ear, in particular those diseases where nerve cell or neuron protection and /or axon regeneration is important, such as spinal cord injury, optic nerve regeneration, neuropathic pain, hearing loss and vestibular diseases such as Meniere’s disease, and other central nervous system diseases. siRNA delivery to the neurons was demonstrated in several disease conditions and we are developing a novel non-invasive delivery to the back of the eye, inner ear and brain. Quark has shown proof of concept for end points, neuroprotection and neural regeneration, in spinal cord injury model for its primary siRNA drug candidate for neuroregeneration and neuropathic pain.

Respiratory and inflammatory diseases program.
Based on siRNA delivery by inhalation Quark has shown proof of concept for a siRNA drug candidate for prevention of primary graft dysfunction an animal model of lung transplantation. This candidate is a drug cocktail that may be useful for treatment of acute lung injury in conditions in addition to lung transplantation since the pathological mechanism of response to ischemic injury is essentially unchanged.

Treatment of chronic diseases by systemic administration.
Quark is currently performing siRNA delivery optimization studies for development potential siRNA drugs for chronic kidney disease and cancer indications.

Fibrotic diseases in collaboration with Nitto Denko.
No effective treatments are available for most of the serious fibrotic diseases and the objective of the collaboration is to develop new siRNA drugs that may offer an effective treatment to fibrotic diseases. The collaboration utilizes Quark’s technology and intellectual property in RNAi, potentially combined with Nitto Denko’s delivery technology to identify, select, optimize and develop a new siRNA drug based on a therapeutic concept and target gene identified by Nitto Denko and its collaborating scientists.